Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies

Alexey V. Danilov, Daniel O. Persky

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences